H1.co Named 2023 Website of the Year by the Health And IT Marketing Community
April 18, 2023 09:00 ET
|
H1
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- H1, the connecting force for global healthcare provider, clinical, science, and research information, is proud to announce that it has been awarded the...
Monopar Announces Camsirubicin Clinical Program Update - Improved Side Effect Profile Seen to Date Compared to Doxorubicin
February 14, 2023 07:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to...
Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
January 09, 2023 01:20 ET
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward...
Crypto Health Market Research Report - Global Forecast to 2027 - Cumulative Impact of COVID-19
December 20, 2022 04:03 ET
|
Research and Markets
Dublin, Dec. 20, 2022 (GLOBE NEWSWIRE) -- The "Crypto Health Market Research Report by Function, End User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ...
Mendus AB: Mendus presenterar positiva överlevnadsdata från ADVANCE II-studien, som utvärderar DCP-001 som underhållsbehandling vid AML, på American Society of Hematology (ASH)
December 12, 2022 13:00 ET
|
Mendus AB
TISDAGEN DEN 13 DECEMBER 2022, KLOCKAN 8.00AM ET/2.00PM CET, GENOMFÖR MENDUS ETT WEBBSÄNT MÖTE, DÄR RESULTATEN SOM PRESENTERATS PÅ ASH KOMMER ATT DISKUTERAS Mendus AB (“Mendus” publ; IMMU.ST),...
Mendus AB: Mendus presents positive survival data from the ADVANCE II trial evaluating DCP-001 as a maintenance therapy in AML at the American Society of Hematology (ASH) meeting
December 12, 2022 13:00 ET
|
Mendus AB
MENDUS TO HOST A WEBCAST TO DISCUSS THE ASH DATA ON TUESDAY, DECEMBER 13, 2022 AT 8.00AM ET/2.00PM CET Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies...
Healthcare Data Leader H1 Releases Its Top Predictions for 2023
December 07, 2022 09:00 ET
|
H1
NEW YORK, Dec. 07, 2022 (GLOBE NEWSWIRE) -- H1, the connecting force for global healthcare provider, clinical, science, and research information, today released its predictions for 2023 to help life...
BioSig’s PURE EP™ System Highlighted in the Journal of Atrial Fibrillation & Electrophysiology
December 06, 2022 08:30 ET
|
BioSig Technologies, Inc.
Westport, CT, Dec. 06, 2022 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
October 11, 2022 07:00 ET
|
NMD Pharma
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis
October 11, 2022 01:00 ET
|
NMD Pharma
NMD Pharma Reports Positive Top-Line Data from a Phase I/IIa Clinical Trial of NMD670 in Patients with Myasthenia Gravis Data provides first clinical proof of the mechanism of action of NMD Pharma’s...